Published in AIDS Res Hum Retroviruses on July 01, 2006
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA (2010) 1.82
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2011) 1.67
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One (2010) 1.01
Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96
Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92
Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine. J Virol (2009) 0.85
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin Vaccine Immunol (2013) 0.83
Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs (2009) 0.80
DNA/MVA Vaccines for HIV/AIDS. Vaccines (Basel) (2014) 0.75
The hitch-hiking effect of a favourable gene. Genet Res (1974) 34.74
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion. Cell (1981) 8.69
Free recombination within Helicobacter pylori. Proc Natl Acad Sci U S A (1998) 8.06
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
MRC image processing programs. J Struct Biol (1996) 6.91
Mucosal shedding of human herpesvirus 8 in men. N Engl J Med (2000) 6.59
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1989) 5.65
Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother (1988) 5.56
Natural selection and the concept of a protein space. Nature (1970) 5.21
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Evolution of genetic redundancy. Nature (1997) 4.95
Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature (1982) 4.93
SYNTHESIS OF A COMPOUND IDENTICAL WITH THE L. CASEI FACTOR ISOLATED FROM LIVER. Science (1945) 4.80
Estimating recombinational parameters in Streptococcus pneumoniae from multilocus sequence typing data. Genetics (2000) 4.61
The changing prevalence of asthma in school children. Clin Allergy (1971) 4.60
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
The Structure and Synthesis of the Liver L. casei Factor. Science (1946) 4.08
Linkage disequilibrium and recombination in hominid mitochondrial DNA. Science (1999) 4.08
Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med (1994) 4.00
The theory of games and the evolution of animal conflicts. J Theor Biol (1974) 3.93
Proteins of Rous sarcoma virus. Virology (1968) 3.84
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science (1983) 3.51
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Retracted A link between virulence and ecological abundance in natural populations of Staphylococcus aureus. Science (2001) 3.44
Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J Mol Evol (1992) 3.44
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
Consensus statement on the live organ donor. JAMA (2000) 3.29
DNA in uninfected and virus-infected cells complementary to avian tumor virus RNA. Proc Natl Acad Sci U S A (1971) 3.25
Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin. J Virol (1986) 3.21
Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc (1976) 3.19
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
Clinical trial of disodium cromoglycate in treatment of asthma in children. Br Med J (1968) 3.10
Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature (1991) 3.10
Prevalence and Natural History of Asthma in Schoolchildren. Br Med J (1961) 3.07
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A (1983) 3.02
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Ferritin: design and formation of an iron-storage molecule. Philos Trans R Soc Lond B Biol Sci (1984) 2.94
At least two regions of the viral genome determine the oncogenic potential of avian leukosis viruses. Proc Natl Acad Sci U S A (1982) 2.84
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science (1995) 2.79
The antibody response in HIV-1 infection. AIDS (1997) 2.79
Polarity and the regulation of the ilv gene cluster in Escherichia coli strain K-12. Mol Gen Genet (1976) 2.78
Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol (1989) 2.77
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis (1997) 2.75
What use is sex? J Theor Biol (1971) 2.75
Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Br J Gen Pract (1996) 2.75
Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet (2000) 2.71
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol (1997) 2.69
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66
Isolation and characterization of proteins from Rous sarcoma virus. Virology (1971) 2.66
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
The prevalence of asthma and wheezing in children. Br J Dis Chest (1976) 2.60
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
DNA polymerase in defective Rous sarcoma virus. Virology (1971) 2.56
Heterogeneity of genetic loci in chickens: analysis of endogenous viral and nonviral genes by cleavage of DNA with restriction endonucleases. Cell (1979) 2.55
Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS (1998) 2.53
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol (2000) 2.49
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant (2006) 2.47
The major evolutionary transitions. Nature (1995) 2.46
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry (1982) 2.43
Validation of an algorithm combining haemoglobin A(1c) and fasting plasma glucose for diagnosis of diabetes mellitus in UK and Australian populations. Diabet Med (2009) 2.38
Nucleotide sequence of Escherichia coli purF and deduced amino acid sequence of glutamine phosphoribosylpyrophosphate amidotransferase. J Biol Chem (1982) 2.32
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
The hitch-hiking effect-a reply. Genet Res (1976) 2.30
Compulsive buying: a report of 20 cases. J Clin Psychiatry (1994) 2.29
Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol (1998) 2.25
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Tumor virus RNA's. Proc Natl Acad Sci U S A (1967) 2.18
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol (1987) 2.14
Isolation of noninfectious particles containing Rous sarcoma virus RNA from the medium of Rous sarcoma virus-transformed nonproducer cells. Proc Natl Acad Sci U S A (1967) 2.13
Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. Science (1988) 2.12
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 2.11
OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant (2015) 2.11
A prescribing incentive scheme for non-fundholding general practices: an observational study. BMJ (1996) 2.09